RMC 035

Drug Profile

RMC 035

Alternative Names: A1M-001; Alpha-1-microglobulin - A1M Pharma; RMC-035; ROSGard; α1-microglobulin - A1M Pharma

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator A1M Pharma AB
  • Class Recombinant proteins; Urologics; Vascular disorder therapies
  • Mechanism of Action Antioxidants; Free radical scavengers; Haemoglobin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Preeclampsia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Preeclampsia
  • Preclinical Acute kidney injury; Radiation injuries

Most Recent Events

  • 14 Nov 2017 A1M completes GLP toxicity studies in Radiation therapies
  • 07 Nov 2017 A1M Pharma files for patent protection for RMC 035 for Radiation injuries (Prevention)
  • 26 Oct 2017 A1M Pharma plans a phase I/II safety clinical trial of RMC 035 in Acute kidney injury (Prevention, In volunteers) and Preeclampsia (In volunteers) in Sweden in the first quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top